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Summary
Heart failure with reduced ejection fraction (HFrEF) is a
common cardiovascular condition with a significant in-
dividual and societal burden. Although it was previously
known as a palliative condition, medical drug therapies that
were developed in the last four decades significantly re-
duced morbidity and mortality of the disease. The corner-
stone of HFrEF therapy remains the blockade of the renin-
angiotensin-aldosterone and the β-adrenergic systems. This
review aims to give an overview and update on established
disease-modifying therapies in HFrEF, discuss advances
and setbacks in the treatment of selected comorbidities and
provide an outlook on upcoming therapies including the
new concept of dual angiotensin receptor and neprilysin in-
hibition.
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Introduction
Heart failure is a clinical syndrome characterised by an in-
ability of the heart to supply tissues with enough blood to
meet their metabolic demands. It has various aetiologies
and can be seen as the common final denominator of many
cardiovascular conditions. In most cases it presents as a
slowly progressing condition termed chronic or congestive
heart failure. The clinical course is often superimposed by
Abbreviations
ACE angiotensin converting-enzyme
ADHF acute decompensated heart failure
ARB angiotensin receptor blocker
ARNI angiotensin receptor neprilysin inhibitor (ARNI)
eGFR estimated glomerular filtration rate
ESC European Society of Cardiology
HFpEF heart failure with preserved ejection fraction
HFrEF heart failure with reduced ejection fraction
LVEF left ventricular ejection fraction
MRA mineralocorticoid receptor antagonist
NYHA New York Heart Association
RAAS renin-angiotensin-aldosterone system
SGLT2 sodium-glucose co-transporter 2
SSRI selective serotonin reuptake inhibitor
acute episodes of worsening of signs and symptoms, also
known as acute decompensated heart failure (ADHF).
The disease poses a major medical and economic chal-
lenge. In a recent European registry, nearly 20% of patients
hospitalised for heart failure died and 50% were rehospit-
alised within the first year [1]. Long-term prognosis was
found to be worse than several malignant cancers [2].
Based on US data, the prevalence of heart failure is expec-
ted to rise by nearly 50% from 2012 to 2030, largely as a
result of the aging population. In this period, heart failure-
related medical costs could rise from 20.9 to 53.1 billion
US dollars [3], with a current average cost of 10.775 US
dollars for a single heart failure hospitalisation [4].
Two types of heart failure are clinically distinguished based
on assessment of systolic function: heart failure with re-
duced ejection fraction (HFrEF) and heart failure with pre-
served ejection fraction (HFpEF). The distinction is relev-
ant as effective disease-modifying therapies are available
only for HFrEF, while no clearly effective evidence-based
treatments are available for HFpEF so far. This review aims
to reflect on current disease-modifying drug treatments for
chronic HFrEF and give an update on selected comorbidit-
ies and upcoming therapeutic concepts. For an overview on
current therapeutic developments in HFpEF, ADHF, med-
ical devices or cardiac biomarkers, interested readers are
referred elsewhere [5–8].
Established disease-modifying
therapies in HFrEF
Classical neurohormonal blockers
Neurohormonal blockers form the basis of disease-modi-
fying therapy in chronic HFrEF (fig. 1). Current first-line
neurohormonal blockers are angiotensin converting-en-
zyme (ACE) inhibitors to reduce renin-angiotensin-aldos-
terone system (RAAS) activation, and β-blockers to reduce
adrenergic effects on the heart and thereby the heart rate.
Combined neurohormonal blockade has revolutionised
treatment of HFrEF since pivotal randomised controlled
trials in the late 1980s and 1990s demonstrated its over-
whelming benefit on hard endpoints. The current 2012
European Society of Cardiology (ESC) guidelines on heart
failure recommend an ACE inhibitor and a β-blocker for all
patients with symptomatic heart failure (New York Heart
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Association [NYHA] class II–IV) and a left ventricular
ejection fraction (LVEF) ≤40% to reduce heart failure hos-
pitalisations and the risk of death [9]. An angiotensin re-
ceptor blocker (ARB) is recommended as an alternative for
patients who do not tolerate an ACE inhibitor. Combination
of an ARB with an ACE inhibitor is recommended only
in patients who do not tolerate a mineralocorticoid recept-
or antagonist (MRA). Evidence-based agents of these drug
classes should be chosen and titrated according to the dos-
ing schemes of randomised controlled trials that demon-
strated their benefit (“start low, go slow, aim high”) [9].
Slow uptitration is especially recommended for β-blockers,
which, because of their negative inotropic effect, can tran-
siently worsen heart failure.
Since the positive results of valsartan/sacubitril (LCZ696)
in HFrEF (details below), guideline recommendations on
RAAS blockers are expected to be revised. The new ESC
guidelines on heart failure will be presented first in May
2016.
Mineralocorticoid receptor antagonists and ivabradine
Mineralocorticoid receptor antagonists (MRAs) represent
the third class of disease-modifying agents in HFrEF since
the striking results of the RALES and EPHESUS trials [10,
11]. An MRA is recommended in patients with an LVEF
≤35% who remain symptomatic (NYHA class II–IV) on
established ACE inhibitor (or ARB) and β-blocker therapy
Figure 1
Overview on current therapies for heart failure with reduced
ejection fraction (HFrEF). The pyramid depicts the step-wise
approach of adding evidence-based treatments as recommended
by the 2012 ESC guidelines [9]. The white boxes reflect additional
factors that are important for the treatment of HFrEF independent of
the standard treatments. Not all therapies are subjects of this
review and for detailed recommendations review of the guidelines
is recommended [5].
*An ARB is recommended when an ACEI is not tolerated
** The position of ARNIs in the treatment cascade will be defined in
the next ESC heart failure guidelines and was thus not more clearly
defined in this figure.
ACEI = angiotensin converting-enzyme inhibitor; ARB = angiotensin
receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor;
CRT = cardiac resynchronisation therapy; ICD = implantable
cardioverter defibrillator; H-ISDN = hydralazine-isosorbide dinitrate;
HTx = heart transplantation; MCS = mechanical circulatory support;
MRA= mineralocorticoid antagonist; omega3 = omega-3
polyunsaturated fatty acids; Q10 = coenzyme Q10.
[9]. The optimal LVEF threshold for initiating spironolac-
tone may be higher, according to a recent post-hoc analysis
of the overall neutral TOPCAT trial [12]. However, a desig-
nated trial in the intermediate LVEF range is necessary for
clear recommendations.
The fourth disease-modifying guideline-recommended
drug is ivabradine, a funny channel blocker that reduces
heart rate in patients with sinus rhythm. Patients who still
remain symptomatic, are in sinus rhythm and have a heart
rate at or over 70 beats per minute despite maximum tol-
erated β-blocker dose should receive ivabradine to reduce
heart failure hospitalisations and death from heart failure,
according to the ESC guidelines [13].
Digoxin and hydralazine / isosorbide dinitrate
Besides these four drug classes and the use of device ther-
apy (not part of this review), two other drugs are currently
recommended for selected patients with HFrEF. Digoxin,
which was popular before the advent of neurohormonal
blockers, may be considered for patients with atrial fib-
rillation in addition to a β-blocker to control heart rate,
in patients who do not tolerate a β-blocker or in patients
who are still symptomatic on established ACE inhibitor (or
ARB), β-blocker and MRA therapy. This recommendation
is mainly based on the DIG trial, which was conducted be-
fore β-blockers were used commonly and which showed a
reduction in heart failure hospitalisations with digoxin [14].
Prospective studies suggested that digoxin therapy is asso-
ciated with increased mortality in patients with atrial fib-
rillation, but this result could not be corroborated in more
recent analyses with more careful adjustment for confound-
ing factors [15]. Regular monitoring of kidney function,
keeping potassium levels in the normal and digoxin levels
in the low-normal range, along with careful assessment of
drug interactions (i.e., with amiodarone) may help reduce
side effects of digoxin such as arrhythmias. The second
drug recommended for selected patients is the combina-
tion of hydralazine with isosorbide dinitrate. It may be con-
sidered as an alternative to an ACE inhibitor or ARB if
neither is tolerated or as an add-on therapy in still sympto-
matic patients, especially in patients of African-American
origin.
Diuretics
Diuretics, although representing one of the oldest drug
classes, still have insufficient data supporting a disease-
modifying effect in chronic HFrEF. The few and small ran-
domised trials available suggest a beneficial effect on mor-
tality compared with placebo [16]. In contrast, in observa-
tional studies diuretic use is dose-dependently associated
with increased mortality [17]. This association may be me-
diated by confounding factors (i.e., sicker heart failure pa-
tients are prescribed higher doses of diuretics). Given that
the association was also observed in a recent propensity-
matched observational study [18], a cautious use of diur-
etics in heart failure seems warranted. In regular clinical
practice, diuretic use is often inevitable to successfully
manage congestion. The ESC guidelines recommend diur-
etic use (preferentially loop diuretics) to relieve symptoms
and signs congestion using the minimally necessary dose.
Based on small clinical studies and pharmacokinetic con-
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siderations, torasemide may be superior to the more com-
monly used furosemide, although evidence is still insuffi-
cient for a widespread recommendation [19].
New evidence on the use of
neurohormonal blockers
Improving titration of neurohormonal blockers
The benefits of ACE inhibitors, ARBs and β-blockers stem
from randomised controlled trials where these agents were
titrated to target doses as tolerated. This strategy is suppor-
ted by prospective evidence showing that titration to higher
target doses is associated with better outcomes than staying
on lower doses [20–22]. However, guideline-recommended
usage of these drugs is still suboptimal in real-world clin-
ical practice. In a large Danish registry, the proportion of
heart failure patients on ACE inhibitors, ARBs, β-blockers
and spironolactone was low, and most patients did not re-
ceive the recommended target doses [23]. This observation
was recently reinforced in the international observational
QUALIFY study that was presented at the 2015 European
Heart Failure Congress [24]. In this study, only 28% of pa-
tients on ACE inhibitors, 7% of patients on ARBs, 15%
on β-blockers and 71% of patients on MRAs received the
recommended target doses. This discrepancy may be ex-
plained by differences between patients included in ran-
domised trials and patients in real-world clinical practice
where a higher morbidity burden may reduce tolerance
of target doses. Doctors’ fear of certain side effects (i.e.,
worsening renal function, changing potassium levels) may
also play a role in not uptitrating therapy. Interestingly, pro-
grammes designed to improve physician education and im-
plementation of guidelines showed that a higher rate of
target doses can be safely achieved in regular outpatient
settings [25, 26]. Lack of communication between hospital
and outpatient physicians may be an issue in this regard.
For instance, heart failure patients eligible for disease-
modifying therapy who were not prescribed a β-blocker
at hospital discharge were significantly less likely to re-
ceive one at follow-up [27]. Given that patients who were
prescribed a β-blocker at discharge have a significantly
lower risk of death and rehospitalisation [27], better physi-
cian training and communication between cardiologists and
general physicians may be helpful in improving guideline
adherence and patient outcomes.
Prescription of β-blockers may also be improved by fo-
cusing on the reduction in heart rate. Some studies in-
dicated that the magnitude of heart rate reduction by β-
blockers rather than the achieved drug dose is important
[28, 29]. The importance of heart rate is also supported
by data on ivabradine indicating that reaching a heart rate
of under 60 beats per minute is associated with the lowest
event rates [30]. However, the optimal target heart rate in
HFrEF patients is still unknown as the large trials focused
on target drug doses rather than achieved heart rate reduc-
tion. Hence, trying to reach the maximum tolerated target
β-blocker doses still appears to be the most evidence-based
approach, which is also supported by a recent analysis [31].
Safety and benefit of RAAS blockers in advanced
chronic kidney disease
A common clinical question is how to use ACE inhibitors,
ARBs and MRAs in patients with moderate to severe
chronic kidney disease. Renal insufficiency is a major co-
morbidity in heart failure and the extent of estimated glom-
erular filtration rate (eGFR) impairment correlates more
strongly with mortality than left ventricular ejection frac-
tion [32]. The question was recently dealt with in a review
of randomised controlled trials [33]. The authors concluded
that there is strong supporting evidence for ACE inhibitors
and MRAs and moderate evidence for ARBs in heart fail-
ure patients with stage 3 kidney disease (eGFR 30–59 ml/
min/1.73 m2). For patients with stage 4–5 kidney disease
(eGFR <30 ml/min/1.73 m2), evidence from randomised
trials for ARBs and MRAs is not available. For ACE in-
hibitors, weak evidence supporting their cautious use in
these stages is available. A recently published propensity-
matched cohort study from Sweden showed that ACE in-
hibitor or ARB use was associated with reduced mortality
in heart failure patients with an eGFR <30 ml/min/1.73 m2
[34]. The relative reduction was similar to that observed in
patients with less severe renal insufficiency and echoes the
results of a prior observational study [35]. Given the sig-
nificantly higher mortality rate of patients with severe ren-
al insufficiency, ACE inhibitor use may be associated with
an even higher absolute mortality reduction in this popula-
tion. This represents a strong rationale for randomised tri-
als in patients with advanced chronic kidney disease. Until
such studies are available, a cautious use of these agents in
chronic kidney disease, with regular monitoring of serum
potassium and creatinine, is warranted. It is worth noting
that a certain degree of worsening renal function and/or in-
crease in potassium levels is to be expected after initiating
ACE inhibitors, ARBs or MRAs. It is part of the mechan-
ism of action of these drugs and does not indicate an ad-
verse outcome [33, 36]. In line with this, a recent obser-
vational study showed that use of high-dose diuretics but
not spironolactone, β-blockers or RAAS blockers was as-
sociated with worse outcomes in worsening renal function
[36]. Regarding ACE inhibitors and ARBs, an increase of
creatinine up to 50% above baseline or an eGFR of up to
25 ml/min/1.73 m2, whichever is smaller, and a potassium
level of ≤5.5 mmol/l is considered acceptable, according
to expert opinion [9]. Regarding MRAs, potassium levels
of ≤5.5 mmol/l and an eGFR of up to 30 ml/min/1.73 m2
are acceptable [9]. Further alterations should result in dose
reductions or discontinuation as necessary. Another factor
that should be appreciated is that renal dysfunction in heart
failure is often caused by venous congestion and not only
by low arterial perfusion [37]. In this situation, decongest-
ive therapy and prevention of decompensations with neuro-
hormonal blockers is a key element to preserve renal func-
tion.
Beta-blockers in HFrEF patients with atrial fibrillation
The benefit of β-blockade in HFrEF patients in sinus
rhythm is firmly established. Recently, new evidence has
emerged for the use of β-blockers in HFrEF patients with
atrial fibrillation. Prior randomised trials included only a
small fraction of HFrEF patients with atrial fibrillation,
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resulting in insufficient power to assess the effect of β-
blockers in this common subpopulation. A recent individu-
al patient data meta-analysis showed that β-blockers reduce
mortality only in HFrEF patients with sinus rhythm but not
in patients with atrial fibrillation [38]. The results are sur-
prising, as the reduction in heart rate by β-blockers was
found to be similar in both groups. As an explanation, the
optimum heart rate in patients with atrial fibrillation may
be higher than in patients in sinus rhythm, according to a
trial comparing strict with lenient rate control [39]. Altern-
ative drugs such as amiodarone are problematic because of
their long term toxicity. Digoxin may be a viable altern-
ative, but, similarly, evidence is insufficient for its first-
line use in atrial fibrillation. In the absence of alternatives
and no evidence of harm, guidelines are currently unlikely
to change and β-blockers will remain first-line therapy in
HFrEF patients with atrial fibrillation. A larger randomised
trial focused on HFrEF patients with atrial fibrillation that
aims to identify the optimum heart rate may help to obtain
more definitive answers.
New evidence on comorbidities in
heart failure
Comorbidities such as diabetes, hypertension, dyslipid-
aemia or depression are a common feature in heart failure
and their coexistence is often associated with a worse pro-
gnosis [40, 41]. Many of the associations can be explained
by the systemic nature of heart failure and the complex in-
terplay of risk factors and their effect on different organs
including the heart. Successful therapy of comorbidities
holds the potential to improve prognosis further in heart
failure patients. While significant advances were made
with certain comorbidities such as with hypertension (i.e.,
better blood pressure control using evidence-based drug
combinations) or atrial fibrillation (i.e., novel oral antico-
agulants), other fields experienced setbacks in recent years.
Some recent developments on selected comorbidities are
reviewed below.
Diabetes
Diabetes is highly prevalent in heart failure and associated
with a worse prognosis [42]. Most available antidiabetic
drugs have been approved on the basis of surrogate markers
such as lowering of blood glucose and glycated haemo-
globin. Evidence from postapproval studies indicates that
this strategy may not have been optimal [43]. Glitazones,
which were once popular oral antidiabetic agents, have
been shown to increase water retention and increase the
risk for heart failure [44]. One of member of this group,
rosiglitazone, may even adversely affect other cardiovascu-
lar outcomes such as myocardial infarction [45, 46]. Sulf-
onylurea drugs may also be problematic, according to ob-
servational studies indicating an increased risk of heart
failure [47, 48]. The newer class of dipeptidyl peptidase-4
inhibitors has also recently been subject of closer scrutiny
when one of its members, saxagliptin, was shown to in-
crease heart failure hospitalisations without demonstrating
a benefit on other cardiovascular events [49]. This increase
was not seen with sitagliptin, but similarly, no reduction in
cardiovascular events was observed [50]. Even insulin may
be problematic in heart failure, partly because of its abil-
ity to increase sodium and water retention. In observation-
al studies, insulin therapy is consistently associated with
worse outcomes in heart failure [51–54]. This observation
may, however, be biased by prescribing patterns, as insulin
is often given to patients with more advanced diabetes [55].
While these data paint a rather dark picture of current an-
tidiabetic drugs, it is reassuring that the current first-line
drug metformin appears to be safe in heart failure and
may even be superior to other established agents [52, 56,
57]. Metformin dose should be adjusted according to ren-
al function and treatment is not recommended in patients
with an eGFR <30 ml/min/1.73 m2 owing to its potential to
cause lactic acidosis.
Beyond established drugs for diabetes, the field of an-
tihyperglycaemic therapy is expected to change signific-
antly since publication of a recent randomised trial on em-
pagliflozin [58]. Empagliflozin belongs to the new drug
class of sodium-glucose co-transporter 2 (SGLT2) inhib-
itors, which increase renal glycosuria. In the EMPA-REG
OUTCOME trial, it significantly reduced both all-cause
and cardiovascular mortality, making it one of the first an-
tihyperglycaemic drugs with a well-documented effect on
hard endpoints. Hospitalisations for heart failure were also
significantly reduced by empagliflozin, possibly owing to
its osmodiuretic effect. This effect appeared to be simil-
ar in magnitude in patients with pre-existing heart failure
in a post-hoc analysis [59]. Further trials focused on heart
failure patients need to show the safety and efficacy of
SGLT2-inhibitors especially in patients with impaired kid-
ney function and concomitant diuretic therapy. Until these
are available, cautious use in heart failure patients may
be worthwhile in light of its osmodiuretic effect and the
chance of delaying initiation of insulin therapy. Urinary
tract infections, genital infections, ketoacidosis and volume
depletion are potential side effects.
Depression
Depression is a common comorbidity associated with a sig-
nificant morbidity burden. The current ESC heart failure
guidelines recommend psychosocial intervention and phar-
macological treatment, preferably with selective serotonin
reuptake inhibitors (SSRIs) [9]. Previously, only one larger
randomised controlled trial with an SSRI in heart failure
patients with depression, SADHART-CHF, was available
[60]. In this trial, sertraline was ineffective in reducing
depression or improving cardiovascular status compared
with placebo. Recently, results of the MOOD-HF trial were
presented at the 2015 ESC heart failure congress [61]. This
trial studied the long-term effects of escitalopram on mor-
tality, hospitalisations and depression symptoms in HFrEF
patients with major depression compared with placebo and,
in addition, to optimal medical therapy. Similar to
SADHART-CHF, escitalopram neither reduced mortality
and hospitalisations, nor reduced depression symptoms
compared with placebo. In a post-hoc subgroup analysis,
escitalopram appeared to worsen mortality and hospital-
isation rates in patients with more advanced heart failure,
whereas it seemed to benefit patients with milder HFrEF.
These results argue for a more cautious use of antidepress-
ants in HFrEF patients. SSRIs can cause significant drug
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interactions as a result of their hepatic metabolism, and
some agents prolong the QT interval and may be arrhyth-
mogenic. In both trials, there was a pronounced reduction
in depression symptoms in both the placebo and the SSRI
group over time, suggesting that depression in heart failure
can also resolve on its own and may be already alleviated
by providing regular patient contacts and optimising heart
failure therapy.
Dyslipidaemia
A relevant controversy also exists on dyslipidaemia and the
question of whether to treat heart failure patients with stat-
ins. In two large randomised controlled trials with rosuvast-
atin, CORONA and GISSI-HF, there was no improvement
in mortality or reduction in coronary events in HFrEF pa-
tients [62, 63]. The results are surprising given that in
CORONA only patients with ischaemic heart failure were
included and in GISSI-HF a majority of patients had heart
failure of ischaemic origin without signs of an interaction
between ischaemic and nonischaemic heart failure. Despite
this neutral effect on mortality, a recent reanalysis of the
CORONA trial showed that rosuvastatin reduced repeat
heart failure hospitalisations [64]. Likewise, in patients
without heart failure, statins may be able to prevent heart
failure hospitalisations but without affecting heart failure
mortality [65]. Several theories about the inefficacy of stat-
ins in heart failure are discussed. One is that in ischaemic
heart failure the ischaemic insult has already occurred and
the attenuation in coronary artery disease progression does
not significantly affect the overall clinical course. Choles-
terol may also serve a protective role in heart failure, for
instance by binding and neutralising endotoxin [66] or by
serving as the basis for the synthesis of protective ster-
oid hormones and cofactors such as coenzyme Q10 [67].
Another theory is that hydrophilic statins like rosuvastat-
in have a lower penetration into heart tissue and lipophilic
statins such as atorvastatin may be more efficacious [68].
Given these uncertainties, the current guidelines do not re-
commend initiating statins in most patients with chronic
heart failure [9].
Gout
Another frequent comorbidity in heart failure is gout. Gout
is often precipitated by diuretic therapy and therapy of
gout attacks is complicated by the cardiac adverse effects
of nonsteroidal anti-inflammatory drugs and corticoster-
oids. Uric acid levels are frequently elevated in heart fail-
ure patients, predict outcome [69] and correlate with gout
risk [70]. It was hoped that the answer was to reduce uric
acid with xanthine oxidase inhibitors. The recently pub-
lished EXACT-HF study compared the effects of allopurin-
ol in HFrEF patients with elevated uric acid levels with
those of placebo [71]. Unfortunately, allopurinol had no
effect on clinical outcomes, echocardiographic measures,
heart failure symptoms and physical capability. The res-
ults echo those of the earlier OPT-CHF study, which failed
to show effectiveness of oxypurinol in HFrEF [72]. A re-
cent Mendelian randomisation study also failed to show an
association of genetically-associated uric acid levels with
heart failure and other cardiovascular diseases [73]. The
negative results may be explained by possible protective
effects of uric acid, which is quantitatively the most im-
portant antioxidant in human blood and may represent a
marker of response to increased oxidative stress [74]. Al-
though general reduction of uric acid in HFrEF regard-
less of symptoms may not be helpful, selective treatment
of HFrEF patients with gout may still be beneficial, as in-
dicated by a prospective study [75]. We therefore recom-
mend restricting xanthine oxidase inhibitor treatment to pa-
tients with a clinical diagnosis of gout and adapting its dose
to renal function. Acute flares should be treated with col-
chicine rather than nonsteroidal anti-inflammatory drugs
[9]. In our centre, we have good experience with short
courses of oral prednisone for the treatment of gout flares,
although we acknowledge its potential to cause acute de-
compensations.
Iron deficiency
Interest in iron deficiency was renewed in recent years
with the advent of intravenous iron therapy. Iron deficiency
is common in HFrEF and its presence correlates with a
worse prognosis [76]. Two randomised controlled trials
showed that intravenous iron therapy in HFrEF patients
with iron deficiency improves physical capability, heart
failure symptoms, quality of life and fatigue [77, 78]. A re-
cent meta-analysis that included both trials showed a sig-
nificant reduction in heart failure hospitalisations [79]. The
effect on hard endpoints such as cardiovascular or all-cause
mortality is still unclear and needs to be tested in a larger
confirmatory trial [80]. To assess HFrEF patients for intra-
venous iron therapy it is recommended to use the same dia-
gnostic criteria that were used in both trials (ferritin <100
ng/ml or ferritin 100–300 ng/ml if transferrin saturation is
<20%) and employ similar dosing schemes.
New therapeutic strategies in HFrEF
Several new therapeutic strategies for chronic HFrEF are
in advanced clinical development. Owing to space con-
straints this review will focus on the newly approved an-
giotensin receptor neprilysin inhibitor (ARNI) valsartan/
sacubitril, third-generation MRAs, new ways to manage
hyperkalaemia as well as approaches to improve cardiac
metabolism. Other notable examples in development are
the soluble guanylate cyclase stimulator vericiguat that
modulates the NO-cGMP system (SOCRATES study pro-
gramme) [81], the renin inhibitor aliskiren, which reduces
RAAS activation (ATMOSPHERE study) [82] or low-dose
anticoagulation with rivaroxaban in HFrEF patients
without an established indication for anticoagulation
(COMMANDER-HF study) [83].
Dual angiotensin receptor and neprilysin blockade
Valsartan/sacubitril is a dual angiotensin receptor neprilys-
in inhibitor that consists of a 1:1 mixture of the ARB
valsartan and the neprilysin inhibitor sacubitril. Neprilysin
inhibitors decrease degradation of various vasoactive pep-
tides, including the potentially cardioprotective natriuretic
peptides. Recently, results were published from the large
PARADIGM-HF trial, which compared valsartan/sacubitril
with enalapril in HFrEF patients [84]. The fixed combin-
ation significantly reduced all-cause and cardiovascular
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mortality as well as hospitalisations for heart failure com-
pared with enalapril. Thereby, PARADIGM-HF was the
first heart failure trial to show that replacement of a class
1A guideline-recommended drug, an ACE-inhibitor, with a
new drug resulted in an incremental improvement in out-
come. The product is already approved in Switzerland and
upcoming heart failure guidelines are expected to be adap-
ted to the new evidence.
To improve clinical implementation, several characteristics
of the drug should to be taken into consideration. First,
PARADIGM-HF employed a run-in period resulting in
only patients tolerating both ACE-inhibitor and valsartan/
sacubitril treatment to enter the randomised treatment peri-
od. Based on the drop-out rates in the run-in period, not
all heart failure patients are expected to tolerate the drug in
real world clinical practice. A common side effect is symp-
tomatic hypotension, which occurs more frequently with
valsartan/sacubitril than with enalapril. Interestingly, des-
pite this observation, hyperkalaemia and renal impairment
were less frequent with valsartan/sacubitril [84]. Another
concern is the risk of angioedema, which was numerically
but not significantly increased in the trial. Because of this,
concomitant therapy with an ACE inhibitor or aliskiren is
contraindicated and combination with another ARB is not
advised. Because of the degradation of amyloid peptides
by neprilysin, an increase in neurodegenerative disease is
a theoretical concern [85]. Although no signals of an in-
crease in dementia or cognitive impairment were seen in
the PARADIGM-HF trial [84], the effect of valsartan/sacu-
bitril on cognitive function will be assessed in more detail
in currently running trials.
Third-generation MRAs and management of
hyperkalaemia
Mineralocorticoid receptor blockade is another area with
new developments. Even though MRAs are highly effect-
ive in HFrEF, one of the main issues limiting their use is
hyperkalaemia [86]. The currently available MRAs spiro-
nolactone and eplerenone have a relatively high tissue con-
centration in the kidney, where mineralocorticoid receptor
antagonism increases renal potassium retention. This led to
the development of finerenone, a nonsteroidal MRA, with
a more balanced tissue distribution between the heart and
kidney. In a phase II study, it led to a smaller increase in
potassium than spironolactone with a comparable reduction
in natriuretic peptide levels [87]. It showed promising res-
ults in a recently presented phase IIb study [88] and devel-
opment is expected to enter phase III.
New strategies to manage potassium levels are also emer-
ging. Two new drugs, sodium zirconium cyclosilicate and
patiromer, which remove potassium by binding it in the
gut, were recently shown to reduce hyperkalaemia in sus-
ceptible patients [89, 90]. Future trials will need to show
their safety and efficacy in heart failure. If positive, they
might allow more consistent MRA use in patients with ad-
vanced chronic kidney disease.
Cardiac metabolism and mitochondrial function
An exciting field in which interest was recently renewed
is cardiac metabolism and mitochondrial function in heart
failure [91]. Research on cardiac metabolism was very act-
ive in the first half of the 20th century but interest waned
with the onset of therapies that primarily focused on hae-
modynamic modulation. Evidence is accumulating that mi-
tochondrial dysfunction plays a central role in heart failure
[92]. One particular feature of heart failure appears to be
the loss of cardiolipin [93]. Cardiolipin is a mitochondrial
membrane lipid that stabilises the electron transport chain
and thereby maintains energy production. SS-31 (Bendav-
ia) is a novel tetrapeptide that binds to cardiolipin and ap-
pears to restore electron transport chain functionality [94].
Phase II studies are ongoing in heart failure and other con-
ditions.
Coenzyme Q10 is a vitamin-like quinone that serves as
an electron carrier between respiratory chain complexes.
It has been under investigation for heart failure for quite
some time, but prior studies were too small and heterogen-
eous to allow firm conclusions [95]. Last year, results from
the largest and most rigorous study, the Q-SYMBIO tri-
al, were published [96]. The trial met its primary endpoint
and showed that coenzyme Q10 reduces all-cause and car-
diovascular mortality as well as heart failure hospitalisa-
tions and symptoms. Hopefully, the results of this trial are
sufficient to renew interest in this nonpatentable substance.
Replication of these findings is important, as is improved
quality control and standardisation of dosing of coenzyme
Q10 supplements before widespread recommendations can
be made.
Conclusion
With the onset of neurohormonal blockade, tremendous
progress has been made in the medical treatment of HFrEF
in the last three decades. New evidence on how to optimise
treatment using established disease-modifying treatments
is available and their implementation may improve pro-
gnosis of our patients. Treatment for several comorbidities
such as diabetes and iron deficiency has improved while
neutral results in others urge us to think over our patho-
physiological concepts. Despite the progress, HFrEF still
remains a deadly condition in 2016 and new effective ther-
apies are urgently needed. New therapeutic principles such
as dual angiotensin receptor neprilysin blockade raise hope
that the burden of heart failure can further be reduced in the
coming years.
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Figures (large format)
Figure 1
Overview on current therapies for heart failure with reduced ejection fraction (HFrEF). The pyramid depicts the step-wise approach of adding
evidence-based treatments as recommended by the 2012 ESC guidelines [9]. The white boxes reflect additional factors that are important for
the treatment of HFrEF independent of the standard treatments. Not all therapies are subjects of this review and for detailed recommendations
review of the guidelines is recommended [5].
*An ARB is recommended when an ACEI is not tolerated
** The position of ARNIs in the treatment cascade will be defined in the next ESC heart failure guidelines and was thus not more clearly defined
in this figure.
ACEI = angiotensin converting-enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; CRT =
cardiac resynchronisation therapy; ICD = implantable cardioverter defibrillator; H-ISDN = hydralazine-isosorbide dinitrate; HTx = heart
transplantation; MCS = mechanical circulatory support; MRA= mineralocorticoid antagonist; omega3 = omega-3 polyunsaturated fatty acids;
Q10 = coenzyme Q10.
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